Amyotrophic Lateral Sclerosis
704
108
143
339
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
97 trials with published results (14%)
Research Maturity
339 completed trials (48% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.2%
58 terminated out of 704 trials
85.4%
-1.2% vs benchmark
6%
43 trials in Phase 3/4
29%
97 of 339 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 339 completed trials
Clinical Trials (704)
Multicenter ALS Imaging Study
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ASSESS ALL ALS Study
QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up
PREVENT ALL ALS Study
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
iBCI Optimization for Veterans With Paralysis
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
HEALEY ALS Platform Trial - Master Protocol
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS
Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS